Thus, the heparanase-1 enzyme activity in the plasma patients with gastrointestinal carcinoma was seen to be approximately twice as much as in the plasma of the unaffected individuals (Student’s t test, P < 0.0001). This evidence concerns the gene HPSE and digestive system carcinoma.